Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study
Journal of Cystic Fibrosis · 2023-07 · 22 (4) · 656-664
DOI: 10.1016/j.jcf.2023.04.008 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cystic Fibrosis, 2023-07. Verfasst von S M Rowe und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 176-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
BACKGROUND: MRT5005, a codon-optimized CFTR mRNA, delivered by aerosol in lipid nanoparticles, was designed as a genotype-agnostic treatment for CF lung disease. METHODS: This was a randomized, double-blind, placebo-controlled Phase 1/2 study performed in the US. Adults with 2 severe class I and/or II CFTR mutations and baseline ppFEV1 values between 50 and 90% were randomized 3:1 (MRT5005: placebo). Six dose levels of MRT5005 (4, 8, 12, 16, 20, and 24 mg) or placebo (0.9% Sodium Chloride) were administered by nebulization. The single ascending dose cohort was treated over a range from 8 to 24 mg; the multiple ascending dose cohort received five weekly doses (range 8-20 mg); and the daily dosing cohort received five daily doses (4 mg). RESULTS: A total of 42 subjects were assigned to MRT5005 [31] or placebo [11]. A total of 14 febrile reactions were observed in 10 MRT5005-treated participants, which were mild [3] or moderate [11] in severity; two subjects discontinued related to these events. Additionally, two MRT5005-treated patients experienced hypersensitivity reactions, which were managed conservatively. The most common treatment emergent adverse events were cough and headache. No consistent effects on FEV1 were noted. CONCLUSIONS: MRT5005 was generally safe and well tolerated through 28 days of follow-up after the last dose, though febrile and hypersensitivity reactions were noted. The majority of these reactions resolved within 1-2 days with supportive care allowing continued treatment with MRT5005 and careful monitoring. In this small first-in-human study, FEV1 remained stable after treatment, but no beneficial effects on FEV1 were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Alabama at Birmingham, USA.
- Maine Medical Center, Tufts University, USA. Electronic address: jzuckerman@cmamaine.com.
- Perelman School of Medicine, University of Pennsylvania, USA.
- University of Florida, Gainesville, USA.
- Nationwide Children's Hospital/the Ohio State University, USA.
- Northwestern University Feinberg School of Medicine, USA.
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- Cystic Fibrosis Foundation
- National Institutes of Health
Zitieren
APA
Rowe, S. M., Zuckerman, J. B., Dorgan, D., Lascano, J., McCoy, K., Jain, M., Schechter, M. S., Lommatzsch, S., Indihar, V., Lechtzin, N., McBennett, K., Callison, C., Brown, C., Liou, T. G., MacDonald, K. D., Nasr, S. Z., Bodie, S., Vaughn, M., Meltzer, E. B., & Barbier, A. J. (2023). Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study. Journal of Cystic Fibrosis, 22(4), 656-664. https://doi.org/10.1016/j.jcf.2023.04.008
Vancouver
Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, et al. Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study. Journal of Cystic Fibrosis. 2023;22(4):656-664. doi:10.1016/j.jcf.2023.04.008
BibTeX
@article{Rowe2023,
author = {Rowe, S M and Zuckerman, J B and Dorgan, D and Lascano, J and McCoy, K and Jain, M and Schechter, M S and Lommatzsch, S and Indihar, V and Lechtzin, N and McBennett, K and Callison, C and Brown, C and Liou, T G and MacDonald, K D and Nasr, S Z and Bodie, S and Vaughn, M and Meltzer, E B and Barbier, A J},
title = {Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study},
journal = {Journal of Cystic Fibrosis},
year = {2023},
volume = {22},
number = {4},
pages = {656--664},
doi = {10.1016/j.jcf.2023.04.008}
}
EUVIMED